First-in human, dose escalation and cohort expansion study for the evaluation of LB-208 (HTR1B antagonist) in adult patients with relapsed or refractory solid tumours and lymphoma

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-509532-25-00

Acronym

LB-208-001

Enrollment

Registered

2024-06-11

Start date

2024-08-07

Completion date

Unknown

Last updated

2025-04-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lymphoma, Solid tumor

None listed

Sex/Gender

All

Age

18 Years to No maximum

Spain

None listed

Source: EU CTIS · Data processed: Feb 4, 2026